US equities |
SPCX $166.81 ▲+4.94% NVDA $236.79 ▲+1.21% MU $1,064.22 ▼-0.99% TSLA $377.41 ▲+1.84% MSFT $526.59 ▲+1.75% SNDK $1,713.75 ▼-0.36% INTC $117.19 ▼-1.79% META $744.88 ▲+2.31%
FinancialContent

Metagenomi Therapeutics, Inc. - Common Stock (NQ:MGX)

1.045 +0.025 (+2.45%)
Delayed Quote Updated: 11:52 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Metagenomi Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
Appointments strengthen financial and scientific leadership to help advance multiple ultra-long-acting incretin and non-incretin therapies toward the clinic 
From ProLynx Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
From Metagenomi Therapeutics, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at Jefferies Global Healthcare Conference in London
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗
Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected ↗
Metagenomi Inc (NASDAQ:MGX) reported Q2 2025 earnings with revenue beating estimates at $8.51M and a narrower loss of -$0.54 per share. Shares dipped slightly amid investor caution over cash burn and... 
Via Chartmill
News headline image
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategy 
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Which stocks are gapping on Wednesday? ↗
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe ↗
OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block OpenAI's $500B Stargate deal. Tensions also rise with Microsoft. 
Via Benzinga
News headline image
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
News headline image
Demystifying Metagenomi: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at Upcoming Scientific Meetings
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week ↗
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025. 
Via Stocktwits
< Previous 1 2 3 4 5 Next >